Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 12;149(11):885-887.
doi: 10.1161/CIRCULATIONAHA.123.066962. Epub 2024 Mar 11.

End-Stage Heart Failure in Cardiac Sarcoidosis

Diana Velikanova  1 , Pauli Pöyhönen  1   2 , Jukka Lehtonen  1 , Piia Simonen  1 , Valtteri Uusitalo  2   3 , Tapani Vihinen  4 , Kari Kaikkonen  5 , Petri Haataja  6 , Tuomas Kerola  7 , Tuomas T Rissanen  8 , Ville Vepsäläinen  9 , Aleksi Alatalo  10 , Päivi Pietilä-Effati  11 , Markku Kupari  1
Affiliations

End-Stage Heart Failure in Cardiac Sarcoidosis

Diana Velikanova et al. Circulation. .
No abstract available

Keywords: cardiomyopathy; heart failure; sarcoidosis.

PubMed Disclaimer

Conflict of interest statement

Disclosures Dr Uusitalo reports advisory board activity with and lecture honoraria from GE Healthcare and Pfizer. Dr Lehtonen reports lecture honoraria from Pfizer. The other authors report no conflicts.

Figures

Figure.
Figure.
Incidence graphs for end-stage heart failure in a 30-year Finnish cohort of biopsy-proven, clinically manifest cardiac sarcoidosis. A, Cumulative incidence in the entire group of 512 patients. B through D, Comparisons of respective graphs across the subgroups of CS stratified by presenting echocardiographic left ventricular ejection fraction (B), elevation of cardiac troponins greater than the reference range (C), and elevation of either brain natriuretic peptide >100 ng/L or N-terminal natriuretic propeptide (NT-proBNP (N-terminal pro-B-type natriuretic peptide) >400 ng/L (D). End-stage heart failure was defined as referral for heart transplantation or death from terminal heart failure. Group comparisons were made using the Gray test. Shaded areas represent 95% CI.
See this image and copyright information in PMC

References

    1. Lehtonen J, Uusitalo V, Pöyhönen P, Mäyränpää MI, Kupari M. Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis. Eur Heart J. 2023;44:1495–1510. doi: 10.1093/eurheartj/ehad067 - PMC - PubMed
    1. Kandolin R, Lehtonen J, Airaksinen J, Vihinen T, Miettinen H, Ylitalo K, Kaikkonen K, Tuohinen S, Haataja P, Kerola T, et al. . Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation. 2015;131:624–632. doi: 10.1161/CIRCULATIONAHA.114.011522 - PubMed
    1. Nordenswan HK, Pöyhönen P, Lehtonen J, Ekström K, Uusitalo V, Niemelä M, Vihinen T, Kaikkonen K, Haataja P, Kerola T, et al. . Incidence of sudden cardiac death and life-threatening arrhythmias in clinically manifest cardiac sarcoidosis with and without current indications for an implantable cardioverter defibrillator. Circulation. 2022;146:964–975. doi: 10.1161/CIRCULATIONAHA.121.058120 - PMC - PubMed
    1. Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, Judson MA, Kron J, Mehta D, Cosedis Nielsen J, et al. . HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11:1305–1323. doi: 10.1016/j.hrthm.2014.03.043 - PubMed
    1. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509. doi: 10.1080/01621459.1999.10474144

Publication types